

AIB1 (RAC3/NCOA3) Antibody (Center) Blocking peptide Synthetic peptide Catalog # BP1082a

Specification

AIB1 (RAC3/NCOA3) Antibody (Center) Blocking peptide - Product Information

Primary Accession

<u>Q9Y6Q9</u>

AIB1 (RAC3/NCOA3) Antibody (Center) Blocking peptide - Additional Information

Gene ID 8202

Other Names

Nuclear receptor coactivator 3, NCoA-3, ACTR, Amplified in breast cancer 1 protein, AIB-1, CBP-interacting protein, pCIP, Class E basic helix-loop-helix protein 42, bHLHe42, Receptor-associated coactivator 3, RAC-3, Steroid receptor coactivator protein 3, SRC-3, Thyroid hormone receptor activator molecule 1, TRAM-1, NCOA3, AIB1, BHLHE42, RAC3, TRAM1

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP1082a was selected from the Center region of human NCOA3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

AIB1 (RAC3/NCOA3) Antibody (Center) Blocking peptide - Protein Information

Name NCOA3

Synonyms AIB1, BHLHE42, RAC3, TRAM1

Function

Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone- dependent fashion. Plays a central role in creating a multisubunit coactivator complex, which probably acts via remodeling of chromatin. Involved in the coactivation of different nuclear receptors, such as for steroids (GR and ER), retinoids (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR) and prostanoids (PPARs). Displays histone acetyltransferase activity. Also involved in the coactivation of the NF-kappa-B pathway via its interaction with the NFKB1 subunit.



Cellular Location

Cytoplasm. Nucleus. Note=Mainly cytoplasmic and weakly nuclear. Upon TNF activation and subsequent phosphorylation, it translocates from the cytoplasm to the nucleus

Tissue Location

Widely expressed. High expression in heart, skeletal muscle, pancreas and placenta. Low expression in brain, and very low in lung, liver and kidney

AIB1 (RAC3/NCOA3) Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

AIB1 (RAC3/NCOA3) Antibody (Center) Blocking peptide - Images

AIB1 (RAC3/NCOA3) Antibody (Center) Blocking peptide - Background

NCOA3 is a nuclear receptor coactivator that interacts with nuclear hormone receptors to enhance their transcriptional activator functions. The encoded protein has histone acetyltransferase activity and recruits p300/CBP-associated factor and CREB binding protein as part of a multisubunit coactivation complex. This protein is initially found in the cytoplasm but is translocated into the nucleus upon phosphorylation.

AIB1 (RAC3/NCOA3) Antibody (Center) Blocking peptide - References

Burwinkel, B., et al., Clin. Cancer Res. 11(6):2169-2174 (2005).Tilli, M.T., et al., Mol. Endocrinol. 19(3):644-656 (2005).Labhart, P., et al., Proc. Natl. Acad. Sci. U.S.A. 102(5):1339-1344 (2005).Beausoleil, S.A., et al., Proc. Natl. Acad. Sci. U.S.A. 101(33):12130-12135 (2004).Reiter, R., et al., Oncogene 23(2):403-409 (2004).